Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo | Zendy

Emilie Alirol | Zendy; David Schrumpf | Zendy; Josué Amici Heradi | Zendy; Andrea Riedel | Zendy; Catherine de Patoul | Zendy; Michel Quéré | Zendy; François Chappuis | Zendy

Open Access

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo

Author(s) -

Emilie Alirol,

David Schrumpf,

Josué Amici Heradi,

Andrea Riedel,

Catherine de Patoul,

Michel Quéré,

François Chappuis

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cis886

Subject(s) - african trypanosomiasis , medicine , eflornithine , nifurtimox , neglected tropical diseases , trypanosomiasis , virology , disease , parasite hosting , biology , trypanosoma cruzi , world wide web , computer science , biochemistry , enzyme , spermidine

Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research